Santarus, Inc. (NASDAQ:SNTS) today announced that data from its Phase I clinical study with its investigational drug SAN-300, a novel antibody that inhibits very late antigen-1 (VLA-1; a1ß1 integrin), will be featured in a poster presentation at the 2013 American College of Rheumatology.
Help employers find you! Check out all the jobs and post your resume.
